Optiver Holding
SKYE icon

Optiver Holding’s Skye Bioscience SKYE Stock Holding History

Optiver Holding’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Hold
3
– – ﹤0.01% 2724
2026
Q1 		$12 Hold
3
– – ﹤0.01% 2277
2025
Q4 		$15 Hold
3
– – ﹤0.01% 2420
2025
Q3 		$79 Buy
+3
New +$91 ﹤0.01% 2605

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Optiver Holding's SKYE Position: Q2 2026 in Review

Optiver Holding held its Skye Bioscience (SKYE) position steady in Q2 2026 at 3 shares worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

Optiver Holding first reported a position in SKYE in Q3 2025 and has held it in 4 quarters since. The position peaked at $79 in Q3 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Optiver Holding held 3 shares of Skye Bioscience worth $14 as of Q2 2026.
  • Optiver Holding left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2724 holding.
  • Optiver Holding first reported a position in Skye Bioscience in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Skye Bioscience position peaked at $79 in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.